Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences By: Acadia Pharmaceuticals Inc. via Business Wire August 30, 2023 at 16:05 PM EDT Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 18th Annual BioPharma Conference Date: Wednesday, September 6, 2023 Location: Boston, MA Format: 1x1 Meetings Morgan Stanley 21st Annual Global Healthcare Conference Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time Location: New York, NY Format: Fireside Chat and 1x1 Meetings TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit Date/Time: Wednesday, September 20, 2023 at 5:00 p.m. Eastern Time Location: Virtual Format: Fireside Chat Cantor Fitzgerald Global Healthcare Conference Date/Time: Tuesday, September 26, 2023 at 11:30 a.m. Eastern Time Location: New York, NY Format: Fireside Chat and 1x1 Meetings Live webcasts of Acadia’s presentations at the Morgan Stanley, Cantor Fitzgerald and TD Cowen conferences will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter. View source version on businesswire.com: https://www.businesswire.com/news/home/20230823759521/en/Contacts Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 media@acadia-pharm.com Investor Contact: Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950 ir@acadia-pharm.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences By: Acadia Pharmaceuticals Inc. via Business Wire August 30, 2023 at 16:05 PM EDT Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 18th Annual BioPharma Conference Date: Wednesday, September 6, 2023 Location: Boston, MA Format: 1x1 Meetings Morgan Stanley 21st Annual Global Healthcare Conference Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time Location: New York, NY Format: Fireside Chat and 1x1 Meetings TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit Date/Time: Wednesday, September 20, 2023 at 5:00 p.m. Eastern Time Location: Virtual Format: Fireside Chat Cantor Fitzgerald Global Healthcare Conference Date/Time: Tuesday, September 26, 2023 at 11:30 a.m. Eastern Time Location: New York, NY Format: Fireside Chat and 1x1 Meetings Live webcasts of Acadia’s presentations at the Morgan Stanley, Cantor Fitzgerald and TD Cowen conferences will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter. View source version on businesswire.com: https://www.businesswire.com/news/home/20230823759521/en/Contacts Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 media@acadia-pharm.com Investor Contact: Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 18th Annual BioPharma Conference Date: Wednesday, September 6, 2023 Location: Boston, MA Format: 1x1 Meetings Morgan Stanley 21st Annual Global Healthcare Conference Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time Location: New York, NY Format: Fireside Chat and 1x1 Meetings TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit Date/Time: Wednesday, September 20, 2023 at 5:00 p.m. Eastern Time Location: Virtual Format: Fireside Chat Cantor Fitzgerald Global Healthcare Conference Date/Time: Tuesday, September 26, 2023 at 11:30 a.m. Eastern Time Location: New York, NY Format: Fireside Chat and 1x1 Meetings Live webcasts of Acadia’s presentations at the Morgan Stanley, Cantor Fitzgerald and TD Cowen conferences will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter. View source version on businesswire.com: https://www.businesswire.com/news/home/20230823759521/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 media@acadia-pharm.com Investor Contact: Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950 ir@acadia-pharm.com